Alzheimer’s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α
Open Access
- 13 May 2020
- Vol. 9 (5), 1215
- https://doi.org/10.3390/cells9051215
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly. Mutations in genes encoding proteins involved in amyloid-β peptide (Aβ) production are responsible for inherited AD cases. The amyloid cascade hypothesis was proposed to explain the pathogeny. Despite the fact that Aβ is considered as the main culprit of the pathology, most clinical trials focusing on Aβ failed and suggested that earlier interventions are needed to influence the course of AD. Therefore, identifying risk factors that predispose to AD is crucial. Among them, the epsilon 4 allele of the apolipoprotein E gene that encodes the major brain lipid carrier and metabolic disorders such as obesity and type 2 diabetes were identified as AD risk factors, suggesting that abnormal lipid metabolism could influence the progression of the disease. Among lipids, fatty acids (FAs) play a fundamental role in proper brain function, including memory. Peroxisome proliferator-activated receptor α (PPARα) is a master metabolic regulator that regulates the catabolism of FA. Several studies report an essential role of PPARα in neuronal function governing synaptic plasticity and cognition. In this review, we explore the implication of lipid metabolism in AD, with a special focus on PPARα and its potential role in AD therapy.This publication has 283 references indexed in Scilit:
- Regulation of Cyclic AMP Response Element Binding and Hippocampal Plasticity-Related Genes by Peroxisome Proliferator-Activated Receptor αCell Reports, 2013
- PPAR-Alpha Agonists as Novel Antiepileptic Drugs: Preclinical FindingsPLOS ONE, 2013
- Amyloid precursor protein controls cholesterol turnover needed for neuronal activityEMBO Molecular Medicine, 2013
- Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonistsCardiovascular Diabetology, 2013
- Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer DiseaseJAMA, 2010
- Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-γ (PPAR-γ)-deficient miceDiabetologia, 2010
- Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in MiceCell, 2009
- Estrogen-induced plasticity from cells to circuits: predictions for cognitive functionTrends in Pharmacological Sciences, 2009
- ApoE Promotes the Proteolytic Degradation of AβNeuron, 2008
- ω-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD StudyArchives of Neurology, 2006